An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency

Giuliana Ferrari, Silvano Rossini, Raffaella Giavazzi, Daniela Maggioni, Nadia Nobili, Monica Soldati, Grace Ungers, Fulvio Mavilio, Eli Gilboa, Claudio Bordignon

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Deficiency of adenosine deaminase (ADA) results in severe combined immunodeficiency (SCID), a candidate genetic disorder for somatic cell gene therapy. Peripheral blood lymphocytes from patients affected by ADA- SCID were transduced with a retroviral vector for human ADA and injected into immunodeficient mice. Long-term survival of vector-transduced human cells was demonstrated in recipient animals. Expression of vector-derived ADA restored immune functions, as indicated by the presence in reconstituted animals of human immunoglobulin and antigen-specific T cells. Retroviral vector gene transfer, therefore, is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.

Original languageEnglish
Pages (from-to)1363-1366
Number of pages4
JournalScience
Volume251
Issue number4999
StatePublished - Mar 15 1991
Externally publishedYes

Fingerprint

Severe Combined Immunodeficiency
Adenosine Deaminase
Cell- and Tissue-Based Therapy
Genetic Therapy
Inborn Genetic Diseases
Immunoglobulins
Lymphocytes
T-Lymphocytes
Antigens
Survival
Genes
Therapeutics
human ADA protein
Severe combined immunodeficiency due to adenosine deaminase deficiency

ASJC Scopus subject areas

  • General

Cite this

Ferrari, G., Rossini, S., Giavazzi, R., Maggioni, D., Nobili, N., Soldati, M., ... Bordignon, C. (1991). An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science, 251(4999), 1363-1366.

An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. / Ferrari, Giuliana; Rossini, Silvano; Giavazzi, Raffaella; Maggioni, Daniela; Nobili, Nadia; Soldati, Monica; Ungers, Grace; Mavilio, Fulvio; Gilboa, Eli; Bordignon, Claudio.

In: Science, Vol. 251, No. 4999, 15.03.1991, p. 1363-1366.

Research output: Contribution to journalArticle

Ferrari, G, Rossini, S, Giavazzi, R, Maggioni, D, Nobili, N, Soldati, M, Ungers, G, Mavilio, F, Gilboa, E & Bordignon, C 1991, 'An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency', Science, vol. 251, no. 4999, pp. 1363-1366.
Ferrari G, Rossini S, Giavazzi R, Maggioni D, Nobili N, Soldati M et al. An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science. 1991 Mar 15;251(4999):1363-1366.
Ferrari, Giuliana ; Rossini, Silvano ; Giavazzi, Raffaella ; Maggioni, Daniela ; Nobili, Nadia ; Soldati, Monica ; Ungers, Grace ; Mavilio, Fulvio ; Gilboa, Eli ; Bordignon, Claudio. / An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. In: Science. 1991 ; Vol. 251, No. 4999. pp. 1363-1366.
@article{1d878d2b2b61463999431210fce3f983,
title = "An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency",
abstract = "Deficiency of adenosine deaminase (ADA) results in severe combined immunodeficiency (SCID), a candidate genetic disorder for somatic cell gene therapy. Peripheral blood lymphocytes from patients affected by ADA- SCID were transduced with a retroviral vector for human ADA and injected into immunodeficient mice. Long-term survival of vector-transduced human cells was demonstrated in recipient animals. Expression of vector-derived ADA restored immune functions, as indicated by the presence in reconstituted animals of human immunoglobulin and antigen-specific T cells. Retroviral vector gene transfer, therefore, is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.",
author = "Giuliana Ferrari and Silvano Rossini and Raffaella Giavazzi and Daniela Maggioni and Nadia Nobili and Monica Soldati and Grace Ungers and Fulvio Mavilio and Eli Gilboa and Claudio Bordignon",
year = "1991",
month = "3",
day = "15",
language = "English",
volume = "251",
pages = "1363--1366",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "4999",

}

TY - JOUR

T1 - An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency

AU - Ferrari, Giuliana

AU - Rossini, Silvano

AU - Giavazzi, Raffaella

AU - Maggioni, Daniela

AU - Nobili, Nadia

AU - Soldati, Monica

AU - Ungers, Grace

AU - Mavilio, Fulvio

AU - Gilboa, Eli

AU - Bordignon, Claudio

PY - 1991/3/15

Y1 - 1991/3/15

N2 - Deficiency of adenosine deaminase (ADA) results in severe combined immunodeficiency (SCID), a candidate genetic disorder for somatic cell gene therapy. Peripheral blood lymphocytes from patients affected by ADA- SCID were transduced with a retroviral vector for human ADA and injected into immunodeficient mice. Long-term survival of vector-transduced human cells was demonstrated in recipient animals. Expression of vector-derived ADA restored immune functions, as indicated by the presence in reconstituted animals of human immunoglobulin and antigen-specific T cells. Retroviral vector gene transfer, therefore, is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.

AB - Deficiency of adenosine deaminase (ADA) results in severe combined immunodeficiency (SCID), a candidate genetic disorder for somatic cell gene therapy. Peripheral blood lymphocytes from patients affected by ADA- SCID were transduced with a retroviral vector for human ADA and injected into immunodeficient mice. Long-term survival of vector-transduced human cells was demonstrated in recipient animals. Expression of vector-derived ADA restored immune functions, as indicated by the presence in reconstituted animals of human immunoglobulin and antigen-specific T cells. Retroviral vector gene transfer, therefore, is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.

UR - http://www.scopus.com/inward/record.url?scp=0025811758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025811758&partnerID=8YFLogxK

M3 - Article

C2 - 1848369

AN - SCOPUS:0025811758

VL - 251

SP - 1363

EP - 1366

JO - Science

JF - Science

SN - 0036-8075

IS - 4999

ER -